Well, this is stunning: Looks like Grail, the Illumina spinout that’s working on an early blood-based screening test for cancer, will be raising a Series B round that clocks in at more than $1 billion.
The company just put out a statement that a number of undisclosed investors are seriously interested in doling out this cash. Fast Company last month had reported that the company was looking to raise $1.7 billion.
About the Author Reprints
Link exchange is nothing else but it is just placing the other person’s website link on your page at appropriate place and other person will also do same in support of you.